Literature DB >> 31510715

[Contrast-enhanced CT and texture analysis of mass-forming pancreatitis and cancer in the pancreatic head].

J J Zhang1, Q Z Li2, J H Wang1, X Chen1, S Ren1, D D Ye1, H F Zhang1, Z Q Wang1.   

Abstract

Objective: To explore the value of contrast-enhanced CT combined with texture analysis in differentiating pancreatic cancer from mass-forming pancreatitis in pancreatic head.
Methods: A retrospective study collected 21 patients with pancreatic head mass-forming pancreatitis confirmed by surgery or biopsy and 47 patients with pancreatic ductal adenocarcinoma confirmed by surgery. The patients visited the Affiliated Hospital of Nanjing University of Chinese Medicine and the First Affiliated Hospital of Wannan Medical College between January 2014 and December 2017. Gender, age and CT findings were collected. The parenchymal phase was selected for texture analysis. The minimum absolute shrinkage and selection operator (LASSO) method was applied for dimensionality reduction.Two independent sample t-tests or Mann-Whitney U test were used for continuous variables based on the Shapiro-Wilks normality test results. Categorical variables were tested by Chi-square or Fisher test. By multivariable regression analysis, CT findings, CT texture analysis, CT findings combined with texture analysis prediction models were established. The receiver operating characteristic (ROC) curve was used to evaluate the diagnostic performance of individual indicators and each prediction model. The Delong test was used to compare the area under the curve (AUC) of each model.
Results: The CT findings prediction model consisted of CT value of lesion on pancreatic parenchymal phase and pancreatic duct penetrating sign. The texture analysis prediction model consists of root mean square and low grey level run emphasis_angle135. The AUC of them were not statistically different (Z=0.150,P>0.05). The combined predictive model had the better diagnostic performance (AUC 0.944, sensitivity 83.0%, specificity 95.2%, +LR 17.43, -LR 0.18) than CT sign prediction model (Z=2.008, P<0.05) and texture analysis prediction model(Z=2.236, P<0.05) were significantly different. Conclusions: The CT findings model and the texture analysis model have equivalent diagnostic performance in the differentiation of mass-forming pancreatitis and pancreatic cancer. The enhanced CT combined with texture analysis model has the best diagnostic efficiency and can further improve the diagnostic ability.

Entities:  

Keywords:  Pancreatic neoplasms; Pancreatitis; Texture analysis; Tomography, X-ray computed

Mesh:

Year:  2019        PMID: 31510715     DOI: 10.3760/cma.j.issn.0376-2491.2019.33.004

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  4 in total

1.  Retrospective Analysis of the Value of Enhanced CT Radiomics Analysis in the Differential Diagnosis Between Pancreatic Cancer and Chronic Pancreatitis.

Authors:  Xi Ma; Yu-Rui Wang; Li-Yong Zhuo; Xiao-Ping Yin; Jia-Liang Ren; Cai-Ying Li; Li-Hong Xing; Tong-Tong Zheng
Journal:  Int J Gen Med       Date:  2022-01-06

Review 2.  Radiomics and Its Applications and Progress in Pancreatitis: A Current State of the Art Review.

Authors:  Gaowu Yan; Gaowen Yan; Hongwei Li; Hongwei Liang; Chen Peng; Anup Bhetuwal; Morgan A McClure; Yongmei Li; Guoqing Yang; Yong Li; Linwei Zhao; Xiaoping Fan
Journal:  Front Med (Lausanne)       Date:  2022-06-23

3.  A systematic review of radiomics in pancreatitis: applying the evidence level rating tool for promoting clinical transferability.

Authors:  Jingyu Zhong; Yangfan Hu; Yue Xing; Xiang Ge; Defang Ding; Huan Zhang; Weiwu Yao
Journal:  Insights Imaging       Date:  2022-08-20

4.  Analysis of the value of enhanced CT combined with texture analysis in the differential diagnosis of pulmonary sclerosing pneumocytoma and atypical peripheral lung cancer: a feasibility study.

Authors:  Chenglong Luo; Yiman Song; Yiyang Liu; Rui Wang; Jianbo Gao; Songwei Yue; Changmao Ding
Journal:  BMC Med Imaging       Date:  2022-02-02       Impact factor: 1.930

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.